Scientists in the Aderem Lab are studying innate responses to HIV, tuberculosis, influenza, and other pathogens that significantly impact global health. Our goal is to define the mechanisms that result in a successful immune response to infection or vaccination and identify targets for therapeutic intervention.

The Aitchison Lab focuses on the development and application of systems biology approaches to infectious diseases.

The Coler Lab focuses on vaccine development and host-directed therapies against a variety of epidemic and pandemic diseases.

The Frenkel Lab aims to: understand the mechanisms that allow HIV to persist during antiretroviral therapy; develop practical, affordable tests to detect drug-resistant HIV; make insights into reservoirs of drug-resistant HIV and illuminate the pathogenesis of HIV-related diseases.

Studying host-pathogen interactions as they occur in tissues.

The Grundner Lab seeks to map the signaling pathways that underlie Mycobacterium tuberculosis’s (Mtb’s) adaptability and pathogenesis. Our studies provide fundamental insight into Mtb biology and identify new targets for therapeutic interference.

The Harrington Lab focuses on intergenerational immune interactions and their effect on susceptibility to infection during pregnancy and infection.

In the Hernandez Lab, we use a combination of genetics, molecular biology, cell culture models and animal models to probe the interactions between mycobacterial pathogens and host immune cells.

The Jaspan Lab seeks to identify correlates of HIV risk at mucosal surfaces, study the role of the commensal bacteria at these mucosal surfaces in modulating immunity, understand immunity of infants born to HIV-infected mothers who are uninfected yet have high morbidity and mortality, and identify vaccination strategie

The Kappe Lab is focused on understanding the complex biology of the malaria parasite and the immune responses to infection, using this information to design transformational interventions that will help win the fight against malaria.

The Kaushansky Lab works with the pathogens of infectious diseases like malaria that infect hundreds of millions of people every year. Our work aims to identify what pathogens need from their host and use this knowledge to prevent and eliminate infectious diseases.

In the Ma Lab, we combine computational and experimental network biology approaches to understand the molecular interactions that determine infection and treatment fate in tuberculosis.

The primary goal of the Minkah lab is to discover and define mechanisms that dictate the generation of durable, protective liver-resident memory T cell responses. Observations from our studies will guide the rational design of highly efficacious malaria vaccines and immune-directed therapies against hepatic maladies.

The Myler Lab uses cutting-edge genomic, bioinformatic and molecular approaches to study gene function and protein structure in a variety of infectious disease organisms.

Our current research is focused in two main areas: (i) understanding the biology of the global pathogen Mycobacterium tuberculosis; and (ii) discovering and developing novel drugs for tuberculosis (TB) that are effective at curing drug sensitive and drug resistant tuberculosis.

The Rajagopal Lab utilizes genetic, molecular, biochemical and proteomic approaches to study infectious diseases caused by bacteria. The lab focuses on the human pathogens group B Streptococcus and Staphylococcus aureus. Research areas of focus include bacteriology, specifically bacterial pathogenesis, bacterial virule

The Sather Lab utilizes state-of-the-art technology to develop novel vaccine immunogens and strategies. In addition, the lab is interested in deciphering the mechanisms of antibody-mediated protective immunity by HIV or malaria vaccination.

The Smith Lab studies the biology of the Plasmodium malaria parasite during the blood stage. The main research interests of the lab are to characterize parasite-host binding interactions and to better understand malaria disease mechanisms. We use this knowledge to design vaccine or disease interventions.

Work in the Sodora Lab primarily focuses on two principal areas of HIV research: HIV transmission and HIV-induced disease and immune factors that impact progression to AIDS.

Research in the Stuart Lab is focused on diseases that are caused by three related parasitic protozoa (Human African trypanosomiasis [sleeping sickness], Chagas disease and Leishmaniasis) and on malaria, which is caused by another protozoan parasite.

Today, tuberculosis (TB) kills more than 1 million people every year, and an effective vaccine is urgently needed. The primary goal of the Urdahl Lab is to perform fundamental research into the immune response to TB that will help inform the rational design of a new and effective vaccine.

The mission of the Vaughan Lab is to alleviate the suffering of those affected by the disease malaria, which kills upwards of 400,000 people, mostly young children, every year.

The Wagner Lab focuses on HIV and other chronic viral infections. The lab studies the mechanism of viral persistence and aims to leverage those insights to engineer improved therapy for chronic infections. The primary focus of the lab is on cell and gene therapy as a novel strategy to treat infectious diseases. We are

Children's Craniofacial Center researchers are currently testing a promising new type of imaging system that create 3-D images.

Dr. Kaalan Johnson and his team use revolutionary 3-D modeling to prepare for a difficult surgery.

7 5 2 1 0 Tips Your actions and what you model for your family can help guide your child to make healthy choices about what they eat and how to stay active.

Seattle Children’s liver specialist Dr. Karen Murray leads the charge to help patients become Hepatitis C free.

Healthy lifestyle program for overweight and obese youth. In partnership with the YMCA.

Jack R. MacDonald’s profound generosity came to light after his passing in September of 2013. Seattle Children’s Research Institute will receive the income of 40 percent of his estate’s $187.6 million chartable trust every year for perpetuity. The funds will act as a launching pad for the discovery of treatments and

El Seattle Children’s Hospital, el Instituto de Investigación de Seattle Children’s y la Fundación para Investigación del Seattle Children’s Hospital ofrecen atención médica pediátrica e investigación de primer nivel con el apoyo de nuestra generosa comunidad.

Seattle Children’s will take a phased approach to the work outlined in our Health Equity and Anti-Racism Action Plan. Learn about our actions and some background on how the anti-racism action plan was collaboratively developed.

Our High-Risk Leukemia Program leaves no stone unturned to help hard-to-treat kids win a race against time.

Dr. Jeff Sperring, CEO, announces Covington & Burling's Detailed Recommendations and 11 Finding Statements based on the assessment of Seattle Children’s efforts to combat racism and promote diversity, equity and inclusion.